+

SG11202010601VA - Antibody variant combinations and uses thereof - Google Patents

Antibody variant combinations and uses thereof

Info

Publication number
SG11202010601VA
SG11202010601VA SG11202010601VA SG11202010601VA SG11202010601VA SG 11202010601V A SG11202010601V A SG 11202010601VA SG 11202010601V A SG11202010601V A SG 11202010601VA SG 11202010601V A SG11202010601V A SG 11202010601VA SG 11202010601V A SG11202010601V A SG 11202010601VA
Authority
SG
Singapore
Prior art keywords
antibody variant
variant combinations
combinations
antibody
variant
Prior art date
Application number
SG11202010601VA
Inventor
Jong Rob De
Frank Beurskens
Simone Oostindie
Aran Labrijn
Kristin Strumane
Janine Schuurman
Kreuk Bart-Jan De
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of SG11202010601VA publication Critical patent/SG11202010601VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202010601VA 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof SG11202010601VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201800195 2018-05-03
DKPA201800644 2018-09-26
PCT/EP2019/061455 WO2019211472A1 (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Publications (1)

Publication Number Publication Date
SG11202010601VA true SG11202010601VA (en) 2020-11-27

Family

ID=66476613

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010601VA SG11202010601VA (en) 2018-05-03 2019-05-03 Antibody variant combinations and uses thereof

Country Status (13)

Country Link
US (1) US12338289B2 (en)
EP (1) EP3788074A1 (en)
JP (2) JP7649139B2 (en)
KR (1) KR20210008380A (en)
CN (1) CN112839958A (en)
AU (1) AU2019264217A1 (en)
BR (1) BR112020022179A2 (en)
CA (1) CA3098486A1 (en)
MA (1) MA52485A (en)
MX (1) MX2020011552A (en)
PH (1) PH12020551808A1 (en)
SG (1) SG11202010601VA (en)
WO (1) WO2019211472A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945021B (en) 2017-02-10 2025-09-12 根马布私人有限公司 Polypeptide variants and their uses
UY39174A (en) * 2020-04-17 2021-10-29 Janssen Biotech Inc POPULATIONS OF BIOSYNTHETIC GLYCOPROTEINS
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
IL305636A (en) * 2021-03-12 2023-11-01 Genmab As Non-activating antibody variants
AU2022369298A1 (en) * 2021-10-20 2024-06-06 Janssen Biotech, Inc. Biosynthetic biparatopic or bispecific binding molecules with enhanced effector functions

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0979281T3 (en) 1997-05-02 2005-11-21 Genentech Inc Process for the preparation of multispecific antibodies with heteromultimers and common components
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE10043437A1 (en) 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
EA013563B1 (en) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL213948B1 (en) 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
KR20110140142A (en) 2002-10-17 2011-12-30 젠맵 에이/에스 Human monoclonal antibodies against CD20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
US7612180B2 (en) 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG10201600950TA (en) 2005-11-28 2016-03-30 Genmab As Recombinant monovalent antibodies and methods for production thereof
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
CN101074261A (en) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
CN101821288A (en) 2007-06-21 2010-09-01 宏观基因有限公司 Covalent diabodies and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PL2235064T3 (en) 2008-01-07 2016-06-30 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN106432503B (en) 2008-12-19 2020-03-06 宏观基因有限公司 Covalent diabodies and uses thereof
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2430051T (en) 2009-05-14 2016-07-11 Inst Nat De La Santé Et De La Rech Medicale Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
PL2975051T3 (en) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120123299A (en) 2009-12-04 2012-11-08 제넨테크, 인크. Multispecific antibodies, antibody analogs, compositions, and methods
DK2544719T3 (en) 2010-03-12 2019-10-14 Debiopharm Int Sa CD37-BINDING MOLECULES AND IMMUNCONJUGATES THEREOF
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
KR101930964B1 (en) 2010-04-20 2018-12-19 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP3281956A3 (en) 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
DK2606064T3 (en) 2010-08-16 2015-04-20 Novimmune Sa Methods for generating multispecific and multivalent antibodies
CN103068847B (en) 2010-08-24 2019-05-07 罗切格利卡特公司 Activatable Bispecific Antibodies
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
KR101973930B1 (en) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
SG193554A1 (en) 2011-03-29 2013-11-29 Roche Glycart Ag Antibody fc variants
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN102250246A (en) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
ES2816078T3 (en) 2011-12-20 2021-03-31 Medimmune Llc Modified Polypeptides for Bispecific Antibody Scaffolds
CN114163530B (en) 2012-04-20 2025-04-29 美勒斯公司 Methods and means for producing immunoglobulin-like molecules
EP2869845B1 (en) * 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
PT2869845T (en) 2012-07-06 2019-12-09 Genmab Bv Dimeric protein with triple mutations
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
JP6377635B2 (en) 2013-01-10 2018-08-22 ゲンマブ ビー．ブイ． Human IgG1 Fc region variants and uses thereof
AU2015248785A1 (en) 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
CA2981183A1 (en) * 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
BR112018011100A2 (en) 2015-12-01 2018-12-04 Genmab B.V. antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition.
CA3010027A1 (en) 2015-12-28 2017-07-06 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN110945021B (en) 2017-02-10 2025-09-12 根马布私人有限公司 Polypeptide variants and their uses
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
KR20200027944A (en) 2017-06-07 2020-03-13 젠맵 비. 브이 Therapeutic antibody based on mutated IGG hexamer
TWI874341B (en) 2018-12-18 2025-03-01 美商健生生物科技公司 Methods of producing heterodimeric antibodies
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof

Also Published As

Publication number Publication date
PH12020551808A1 (en) 2021-07-26
JP7649139B2 (en) 2025-03-19
BR112020022179A2 (en) 2021-02-02
US12338289B2 (en) 2025-06-24
MX2020011552A (en) 2020-11-24
JP2025085008A (en) 2025-06-03
EP3788074A1 (en) 2021-03-10
US20210238296A1 (en) 2021-08-05
CN112839958A (en) 2021-05-25
MA52485A (en) 2021-03-10
AU2019264217A1 (en) 2020-12-17
CA3098486A1 (en) 2019-11-07
WO2019211472A1 (en) 2019-11-07
JP2021522303A (en) 2021-08-30
KR20210008380A (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL267942B (en) Anti-cd73 antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL268734A (en) Anti-lag-3 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL268700A (en) Anti-phf-tau antibodies and uses thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL269134A (en) Anti-par2 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL273157A (en) Axl-specific antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL272476A (en) Anti-apelin antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载